Heron Therapeutics, Inc. — Q2 2023 Form 10-Q Summary
Business Context and Reporting Period
Heron Therapeutics is a commercial-stage biotechnology company developing and commercializing products for acute-care and oncology patients. Its commercial portfolio includes ZYNRELEF, APONVIE, CINVANTI and SUSTOL. The filing covers the three and six months ended June 30, 2023; financial statements are unaudited.
APONVIE became commercially available in the U.S. in March 2023. Heron paused development of HTX-034 following changes to its executive management team to reassess the program and market opportunity.
Key Financial Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Net product sales | $31.8 million, up 15.0% | $61.4 million, up 20.1% |
| Gross profit | $11.6 million | $24.4 million |
| Gross margin | 36.5% | 39.7% |
| Loss from operations | $(42.4) million | $(75.5) million |
| Operating margin | (133.5%) | (123.0%) |
| Net loss | $(42.1) million | $(74.8) million |
| Net loss per share | $(0.35) | $(0.63) |
| Net cash used in operating activities | Not separately reported | $(52.1) million |
Product sales were led by CINVANTI at $24.5 million in the quarter and $47.3 million year to date. Q2 ZYNRELEF sales were $4.1 million, SUSTOL sales were $2.8 million and APONVIE sales were $0.3 million.
At June 30, 2023, cash and cash equivalents were $13.5 million, short-term investments were $19.8 million and total liquidity was $33.2 million. Accounts receivable were $76.7 million and inventory was $44.6 million. Total liabilities were $240.5 million, including $149.4 million of convertible notes payable. Stockholders’ equity was a deficit of $39.3 million.
Material Changes Versus the Prior Comparable Period
- Net product sales increased by $4.1 million in Q2 and $10.3 million for the first six months, driven by growth in ZYNRELEF, CINVANTI and SUSTOL and the launch of APONVIE.
- Research and development expense declined to $17.6 million from $28.8 million in Q2 and to $31.4 million from $70.9 million year to date, primarily because ZYNRELEF scale-up and validation work was substantially completed in 2022 and personnel costs decreased.
- General and administrative expense increased to $15.2 million from $9.2 million in Q2 and to $26.1 million from $18.7 million year to date, primarily due to executive departure costs and ongoing CINVANTI patent litigation costs.
- Sales and marketing expense declined to $21.2 million from $22.9 million in Q2 and to $42.4 million from $46.4 million year to date, reflecting lower ZYNRELEF commercialization costs and improved operating efficiency.
- Cost of product sales included ZYNRELEF inventory write-offs of $7.5 million in Q2 and $12.8 million year to date, compared with $2.5 million in the corresponding 2022 periods. These charges reduced gross margin.
- Net cash used in operating activities improved to $52.1 million from $72.3 million year to date, primarily because of the lower net loss, although working-capital movements remained a use of cash.
Guidance, Outlook, Risks and Unusual Items
- Management stated that, including subsequent financing proceeds, available liquidity should satisfy anticipated cash requirements for at least one year from the filing date. This assessment depends on the current operating plan and projections.
- In July 2023, Heron completed a private placement of common stock and pre-funded warrants, generating estimated net proceeds of $29.7 million.
- In August 2023, Heron borrowed $24.5 million under a working capital facility that permits aggregate principal borrowings of up to $50.0 million. The facility initially bears cash interest at 9.95% plus 1.5% paid-in-kind interest and includes lender warrants.
- The company expects total June 2023 restructuring expense of $2.8 million, with remaining expense expected in the third and fourth quarters of 2023. Executive departure activities are expected to total $13.4 million, including $8.7 million of non-cash stock compensation; $2.2 million remained to be recognized after June 30.
- The FDA extended the PDUFA goal date for the ZYNRELEF supplemental application to January 23, 2024. Heron does not plan to commercially launch ZYNRELEF in the U.K. or Canada.
- Heron is litigating against Fresenius Kabi regarding proposed generic CINVANTI. A five-day bench trial is scheduled for June 24, 2024; FDA approval of the ANDA may be delayed until the earlier of December 14, 2024 or resolution of the litigation.
- Product sales and receivables are highly concentrated: three customers represented 98.9% of Q2 sales, 98.8% of year-to-date sales and 99.5% of accounts receivable at June 30, 2023.
- The company continues to incur substantial operating losses and has a large accumulated deficit of $1.87 billion. Its ability to reach profitability depends on product growth, pricing and reimbursement, competition, manufacturing execution and additional financing.
Most Important Facts for Investors to Verify
- Whether ZYNRELEF sales growth and the planned label expansion support improved utilization and margins after the inventory write-offs.
- The commercial trajectory, reimbursement and adoption of newly launched APONVIE.
- Actual cash burn, liquidity runway and borrowing availability under the working capital facility, including high interest costs and warrant dilution.
- The outcome and timing of the CINVANTI patent litigation and any potential generic competition.
- The financial impact of restructuring, executive turnover and ongoing legal costs.
- Customer concentration, accounts-receivable collections and the accuracy of product-return, rebate and discount accruals.
- The FDA decision on the expanded ZYNRELEF indication by the revised January 23, 2024 goal date.